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INTRODUCTION
Insulin resistance is a major driver of dyslipidemia and cardiovascular risk. However, the mechanisms linking alterations in insulin signaling with dyslipidemia are incompletely understood. The liver is a key tissue for integrating the signaling of insulin and glucose: it is responsible for maintaining blood glucose concentration, it acts as a reservoir for delivery of glucose to the bloodstream when it is necessary 1 , and it is a key target for insulin's inhibition of hepatic glucose production 2 . Moreover, the liver is critical to the regulation of lipoproteins: very low-density lipoprotein (VLDL) particles and nascent high-density lipoprotein (HDL) particles are synthesized and secreted into the circulation by the liver. Hepatocytes are the primary site of uptake for LDL particles, and HDL particles also return to the liver to deliver cholesterol removed from other tissues through the process of reverse cholesterol transport 3 . Therefore, liver insulin signaling is a potential contributor to insulin resistance-associated dyslipidemia.
FoxO transcription factors are critical mediators of insulin action on gene expression in hepatocytes, where they are involved in regulating glucose and lipid metabolism [4] [5] [6] [7] [8] . Consistent with this, mice with liver-specific knockout of all three insulin-sensitive FoxO isoforms (L-FoxO1, 3, 4) have reduced hepatic glucose production and increased de novo lipogenesis 5, 9, 10 . These phenotypes are associated with altered expression of genes related to glucose versus fatty acid production, including reduced glucose-6-phosphatase catalytic subunit (G6pc) and increased glucokinase 5, 9, 11, 12 . L-FoxO1,3,4 mice also have defects in bile acid synthesis and HDL-mediated reverse cholesterol transport 13, 14 .
Based on unbiased transcriptomics from livers of L-FoxO1,3,4 mice 5 , one of the most downregulated genes in the livers of these mice is Apolipoprotein M (Apom). ApoM is a secreted protein that is bound to lipoprotein particles, and is predominantly enriched-more than 95%-in HDL 15 . ApoM is a chaperone for sphingosine-1-phosphate (S1P) in plasma HDL 16 . S1P is a bioactive sphingolipid that signals through a series of G protein-coupled receptors (S1P receptors 1-5) present on a variety of cell types 17, 18 . In plasma, around 65% of S1P is carried by HDL-bound ApoM and the remainder is found in the lipoprotein depleted (LPD) fraction, presumably associated to albumin 16, 19 . Importantly, S1P induces differential effects depending on whether it is associated with ApoM or albumin 20, 21 . This is exemplified by the ability of the HDL-ApoM-S1P complex to enhance endothelial function 16, [22] [23] [24] .
In this work, we report that hepatic FoxOs promote hepatic ApoM expression and are required for S1P to associate with HDL particles. This suggests a novel mechanism whereby hepatic FoxOs determine HDL composition and function.
RESULTS

FoxOs are required for hepatic ApoM expression.
To examine the effects of hepatic FoxO deletion on apolipoprotein gene expression, we queried our microarrays from prior experiments 5 . We found that livers from L-FoxO1,3,4 mice had a substantial reduction in the mRNA expression of Apom, compared to littermate controls. To confirm this, we carried out qPCR and western blots from liver tissue and found that L-FoxO1,3,4 mice have ~90% reductions in Apom mRNA expression and nearly undetectable ApoM protein in liver ( Fig. 1a-b) .
The effect of FoxO deletion to reduce hepatic Apom expression might be due to a primary effect of FoxO ablation or an acquired or compensatory defect, due to long-term genetic loss of FoxOs. Thus, we explored the hepatic Apom expression in neonatal mice. The decreases in Apom were identified as early as post-natal day 2 in neonatal L-FoxO1,3,4 mice, compared to littermate controls ( Fig. 1c) . To test the effect in adult mice, we examined mice with an acute depletion of FoxOs. We transduced adult FoxO1 F/F , FoxO3 F/F , and FoxO4 F/Y control mice with an adenoassociated virus expressing Cre recombinase under the hepatocyte-specific Tbg promoter (AAV8.Tbg.Cre). We verified that one month after the injection, there was a >80% depletion of FoxO mRNA expression as well as low levels of G6pc, a known target of FoxO transcriptional activation 14 . In these FoxO-depleted mice, we found that the Apom mRNA expression is significantly decreased (Fig. 1d) . These findings demonstrate that hepatic FoxOs are required for hepatic Apom expression.
ApoM is a transcriptional target of FoxO.
Hepatic FoxOs have been suggested to modulate some liver metabolic pathways via indirect effects on non-hepatic tissues 25, 26 . Therefore, we examined whether FoxOs regulate Apom in primary hepatocytes, using mutant versions of FoxO1. The FoxO1 protein structure contains three Akt phosphorylation sites that mediate its nuclear exclusion, a transactivation domain, and a DNA binding domain ( Fig. 2a) 27, 28 . We isolated primary hepatocytes from wild-type mice and transduced them with a FoxO1-ADA mutant, which has the three Akt phosphorylation sites mutated, causing FoxO1 to be constitutively nuclear 29 . The FoxO1 ADA mutant increased G6Pc and Apom expression ( Fig. 2a) . FoxOs can regulate gene expression by direct DNA binding or by acting as a transcriptional coregulator [30] [31] [32] [33] . Next we evaluated if the DNA binding domain of FoxO1 is required for the induction of Apom. We used a FoxO1-ADA-DBD mutant, which has the ADA mutation, and it has a second mutation in the DNA binding domain. We observed that the ADA-DBD mutant of FoxO1 is unable to activate G6Pc or Apom expression ( Fig. 2b) . We also transduced primary hepatocytes with a dominant negative version of FoxO1 that lacks the transactivation domain (FoxO1-Delta256) 34 . We observed that FoxO1-Delta256 decreases G6Pc and Apom expression ( Fig. 2c) . These data show that FoxOs promote hepatic Apom expression by direct actions in hepatocytes, and the DNA binding and transactivation domains are required.
FoxOs are required for S1P binding to HDL
ApoM is a secreted protein that is found mostly on HDL 16 . Thus, we examined whether FoxOs regulate the levels of ApoM in total plasma. Western blot from total plasma showed that ApoM protein levels are nearly absent in L-FoxO1,3,4 ( Fig. 3a) . ApoM is a chaperone of S1P 16 . We measured S1P by Liquid Chromatography-Mass Spectrometry. There were no differences in total plasma S1P levels between genotypes (Fig. 3b) . Next, we examined whether ApoM and S1P are affected in plasma lipoproteins from L-FoxO1,3,4 mice. We fractionated lipoproteins by size, using fast protein liquid chromatography, and measured S1P and apolipoprotein content. This revealed that control mice have two peaks of S1P: one in the HDL, and one in the lipoproteindepleted fractions, presumably bound to albumin ( Fig. 3c) . On the other hand, L-FoxO1,3,4 mice showed a marked reduction of S1P in HDL, and an increase of S1P in the lipoprotein-depleted fraction ( Fig. 3c) . Western blots of these fractions showed that ApoA1, the main apolipoprotein of HDL, was present in both genotypes. However, ApoM was nearly absent from L-FoxO1,3,4 mice ( Fig. 3d) . Therefore, hepatic FoxOs are required for ApoM and S1P association with HDL.
We carried out the same analysis in mice that were fed the western diet for three weeks. Again, we observed that in the absence of hepatic FoxOs, levels of S1P and ApoM in HDL were largely depleted ( Fig. 3e-f ).
Rescuing the expression of ApoM in L-FoxO1,3,4 deficient mice normalizes the S1P distribution
We next tested whether ApoM rescue in the livers of FoxO deficient mice is sufficient to normalize S1P distribution. We transduced L-FoxO1,3,4 and control mice with either an adenovirus expressing ApoM (Ad-ApoM), or a control virus (Ad-GFP). Eight days after virus injection, we harvested tissues and found that at our dose of the virus, the L-FoxO1,3,4+Ad-ApoM mice express similar levels of hepatic Apom mRNA as control mice transduced with Ad-GFP ( Fig. 4a) , demonstrating efficient rescue of Apom. We also measured hepatic FoxO1 expression levels and verified that there is no effect of ApoM virus injection on FoxO1 expression ( Fig. 4b) . We fractionated lipoproteins by sequential density ultracentrifugation, and by western blot of the HDL fractions, we confirmed the rescue of ApoM protein levels in the L-FoxO1,3,4 mice ( Fig. 4c) . Although there was no significant effect on total plasma S1P levels ( Fig. 4d) , rescuing ApoM in L-FoxO1,3,4 mice caused a normalization of the S1P distribution ( Fig. 4e) . We conclude that loss of ApoM is the cause of the impaired S1P association with HDL in L-FoxO1,3,4 mice.
ApoM is not involved in glucose regulation by FoxOs.
Kurano et al. 35 overexpressed ApoM by several-fold in wild-type mice using adenovirus gene transfer and observed that ApoM overexpression increased glucose tolerance, potentially due to increased insulin secretion. Because FoxOs are known to regulate glucose homeostasis, we tested whether rescuing ApoM in L-FoxO1,3,4 mice had any effect on glucose tolerance. As expected, we found that the L-FoxO1,3,4 mice have better glucose tolerance than littermate control mice 5, 9 , but rescuing ApoM in these mice had no effect ( Fig. 4f) . We conclude that ApoM is not involved in the effects of FoxOs on glucose homeostasis.
ApoM and HDL-associated S1P are decreased in in db/db, but not diet-induced obese mice. FoxO-deficient mice are a model of constitutive insulin action onto FoxO, whose activity is normally suppressed by insulin. It's widely held that FoxOs are constitutively active in insulin resistance, due to impaired Akt-mediated phosphorylation 36 . On the other hand, it's also been suggested that the absence of FoxOs may mimic certain conditions of hyperinsulinemia 5, 37 because FoxOs are exquisitely sensitive to very low levels of insulin 38 . Thus, we investigated whether the ApoM expression and S1P distribution are affected in independent mouse models of hyperinsulinemia and insulin resistance.
Leptin receptor deficient Db/db mice are a well-established model of diabetes and obesity. We examined db/db mice at two different ages, 13 and 25 weeks. The body weight, glucose, and insulin levels were higher in the db/db mice as expected (Supplementary Fig. 1a-c) . We predicted that Apom liver expression would be increased in db/db mice, due to insulin resistance and FoxO activation. In contrast to our expectations, we observed that hepatic Apom expression is reduced in db/db mice ( Fig. 5a-b) . Consistent with this, ApoM protein levels are reduced in total plasma ( Fig. 5c) and specifically in the HDL fraction from db/db mice ( Fig. 5d-e) . While there were no differences in total plasma S1P levels (Fig. 5f) , the db/db mice showed a reduction of S1P in HDL, and an increase of S1P in the lipoprotein depleted fraction (Fig. 5g) .
We had originally expected that FoxOs would be constitutively activated in db/db mice, so we investigated whether the expression of other known FoxO targets are affected in these mice. We observed that G6Pc was not elevated in our db/db mice at either age, although Igfbp1 was (Supplementary Fig. 1d) . Gck is normally suppressed by FoxOs 5,12 , but it was increased in 13week-old db/db mice (Supplementary Fig. 1d ). Therefore, based on these canonical FoxO targets in the glucose metabolism pathway, there is no clear induction of FoxO targets that would indicate constitutive FoxO activation. On the other hand, we have previously reported that Scarb1 and Lipc, two hepatic genes involved in HDL-cholesterol uptake into liver, are induced by FoxOs 14 . We found both Scarb1 and Lipc are reduced in db/db mice (at 25 weeks and both ages, for Scarb1 and Lipc, respectively) ( Supplementary Fig. 1e ). This suggests the possibility that in db/db mice, a subset of FoxO target genes related to lipoprotein metabolism are inactivated, through an unknown mechanism.
The second insulin resistance model that we studied were diet-induced obese mice. We fed C57BL/6J mice with a high fat diet starting at 6-weeks of age, until harvesting tissues when the mice were 13 or 29 weeks old. We observed an increase in the body weight, glucose, and insulin levels of the high fat-fed mice, as expected (Supplementary Fig. 2a-c) . But we did not see an effect on the Apom mRNA expression or at the protein level ( Supplementary Fig. 2d-f) . Altogether, these data suggest that ApoM expression and S1P binding to HDL are affected in some, but not all, models of hyperinsulinemia and insulin resistance.
DISCUSSION
Our findings show that FoxOs promote hepatic ApoM expression, and the FoxO-ApoM pathway is required for S1P to associate with HDL. Moreover, our data indicate that the majority of plasma ApoM arises from hepatic secretion, and that hepatic ApoM is required only for HDL-associated S1P, not total plasma S1P. We recently demostrated that hepatic FoxOs also promote clearance of HDL-cholesterol, by promoting expression of Scarb1, encoding scavenger receptor BI (SR-BI), and Lipc, encoding hepatic lipase 14 . Together with the novel data in this manuscript, these findings suggest that there are at least two independent mechanisms by which hepatic FoxOs regulate HDL composition. S1P is a signaling molecule, and it is been reported that S1P can induce differential effects, depending on its chaperone, either ApoM or albumin 16, [20] [21] [22] [23] . The molecular mechanisms for the differential effects between ApoM-and albumin-bound S1P remain under investigation. One possibility is the accessibility of S1P. Within the structure of ApoM, S1P interacts specifically with an amphiphilic pocket in the lipocalin fold 16 . Albumin serves as a promiscuous binding protein for various hydrophobic molecules, but it is unknown specifically how S1P binds to albumin. This raises the possibility that being bound to ApoM allows S1P to interact more efficiently with S1P receptors, although the binding of ApoM and S1P is strong, so the spontaneous release of S1P from ApoM is unlikely 39 . Another possibility invokes the preferential binding to HDL to certain cell types. SR-BI is a cell-surface receptor that binds HDL, and it has been shown to interact with S1PRs and allow activation by HDL-bound S1P 40 .
What is the consequence of FoxO inducing apoM and HDL-associated S1P? One possibility we considered was that this would play a role in FoxOs' regulation of glucose homeostasis. This was suggested by data showing that several-fold overexpression of ApoM in wild-type mice improves glucose tolerance, and that ApoM-containing lipoproteins can stimulate insulin secretion from a mouse insulinoma cell line 35 . While L-FoxO1,3,4 mice per se have improved glucose tolerance, the rescue of ApoM in our experiment had no effect on glucose tolerance.
On the other hand, it is possible that decreased hepatic expression of ApoM may have other local and systemic consequences. For example, multiple publications have suggested a role for apoM-S1P in endothelial function, including increased phosphorylation of eNOS, decreased expression of immune cell adhesion molecules, and increased endothelial barrier function 16, [22] [23] [24] . Thus, it is possible that the low ApoM-S1P in L-FoxO1,3,4 mice cause them to have impairments in endothelial functions.
It is of interest to compare L-FoxO1,3,4 mice to Apom -/mice. L-FoxO1,3,4 mice have a neartotal absence (~90% reduction) of hepatic Apom mRNA and protein, and a similarly potent reduction of plasma ApoM. This causes a substantial reduction in HDL-associated S1P. However, the S1P bound to albumin is compensatorily increased, such that L-FoxO1,3,4 mice have no differences in total plasma S1P levels compared to the control mice. These findings indicate that: (i) most ApoM in plasma arises from hepatocytes and (ii) hepatic ApoM is either not required for maintaining total plasma S1P content, or very low levels of ApoM are sufficient. In contrast, whole-body Apom -/mice have a reduction in total plasma S1P by 46% compared to wild-type mice 16 . The contrast between these two mouse models suggests the possibility that other, nonhepatocyte cells that express ApoM are involved in maintaining total plasma S1P levels.
FoxOs are inactivated by insulin, and it is widely believed that they are constitutively active in settings of insulin resistance 36 . Interestingly, in insulin resistant db/db mice, where FoxOs may be expected to be constitutively active, ApoM is reduced. Xu et al. previously showed that hepatic Apom expression and the levels of ApoM in plasma are significantly lower in db/db mice 41 . We confirmed these findings in multiple cohorts of db/db mice, at different ages (12-13 weeks and 25 weeks), and extended them by showing that db/db mice have reductions in the levels of S1P bound to HDL, with no differences in total plasma S1P levels. Consistent with the low ApoM, we also found that other FoxO targets involved in HDL homeostasis, Scarb1 and Lipc 14 are also reduced in db/db mice. This is in contrast to other canonical FoxO targets in the glucose metabolism pathway, whose expression are varyingly suggestive of FoxO being active, inactive, or unaffected in these db/db mice. Thus, the molecular basis underlying the decrease specifically in lipoproteinrelated FoxO targets remains to be elucidated. Potential explanations may be suggested by comparing the db/db mice with the diet induced obese mice, which had no differences in Apom expression. In the db/db mice the levels of glucose and insulin are increased ~2-fold and ~20-30fold, respectively. These changes were milder in the diet induced obese mice, where glucose increased 1.4-fold and insulin increased 6-8-fold. Perhaps the extreme hyperinsulinemia in db/db mice is capable of inactivating a subset of FoxOs. Another possibility is that FoxOs' effects on ApoM expression could be sensitive to glucose levels or other hormones. FoxOs are regulated by multiple different posttranslational modifications in addition to the effects of insulin signaling to suppress FoxO activity via Akt-mediated phosphorylation and nuclear exclusion 42, 43 . In response to hyperglycemia and oxidative stress, FoxOs are acetylated, which causes accelerated FoxO degradation 44 . In response to glucagon and downstream calcium signaling, FoxOs are phosphorylated on alternative phosphorylation sites that cause its activation 45, 46 . Thus, in certain settings of murine insulin resistance, a subset of FoxOs may be inactivated, causing decreased expression of Apom and potentially other FoxO targets.
Individuals with type 2 diabetes have low levels of high-density lipoprotein (HDL)-cholesterol, and these low HDL-cholesterol levels are inversely correlated to cardiovascular disease. However, clinical trials have demonstrated that raising HDL-cholesterol per se is generally insufficient to reduce coronary disease 47 . It is possible that other aspects of HDL are defective in diabetes, contributing to cardiovascular risk. A recent paper has shown that diabetes patients have reduced S1P-HDL levels and impaired HDL cardioprotective function 48 . Moreover, plasma ApoM and S1P levels are inversely associated with mortality in diabetes patients 49 . These findings suggest that an alternative approach to lowering cardiovascular risk in diabetes would be to increase ApoM and S1P, which may have endothelium-protecting effects 16, [22] [23] [24] . 
